^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DNMT3A overexpression

    i
    Other names: DNMT3A, DNA Methyltransferase 3 Alpha, DNA (Cytosine-5-)-Methyltransferase 3 Alpha, DNA (Cytosine-5)-Methyltransferase 3A, DNA MTase HsaIIIA, DNA Cytosine Methyltransferase 3A2, DNA Methyltransferase HsaIIIA, DNMT3A2, Dnmt3a
    Entrez ID:
    1788
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: novel phenotype modifiers in Li-Fraumeni syndrome? (PubMed, Gene)
    With this study, we presented additional evidence about the importance of analyzing miRNA genes that could indirectly regulate p53 expression, and, therefore, may modulate the LFS phenotype, such as those of the miR-34 family.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MIR34A (MicroRNA 34a-5p) • MIR34B (MicroRNA 34b)
    |
    TP53 expression • DNMT3A overexpression
    almost4years
    Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population. (PubMed, Afr Health Sci)
    We found a significant relationship between rs61764370 (T / G) polymorphism and lung cancer risk, the GT genotype (OR: 6.25; 95% CI = 2.605-15.00; P= 0.000) and G allele (OR: 5.25; 95% CI = 2.259-12.208; P= 0.000) were significantly associated with an increased risk of lung cancer. According to our findings, there is a significant relationship between the KRAS rs61764370 polymorphism and lung cancer risk in Iranian population and this polymorphism may be used as a marker in detection of lung cancer in the future.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    DNMT3A overexpression